Peptides / Sexual health and hormones

Synthetic analog · 10 amino acids · 1,311.4 Da

Triptorelin (Trelstar, Decapeptyl)

ApprovedBanned in sport

Triptorelin (Trelstar) is a GnRH agonist used in approved medicines to lower sex hormones, with uses that differ by product and country. Studies in people measured sex hormones and side effects, and it is banned in sport. PepBank shows 1,050 results on triptorelin from 210 studies in people, and 288 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as D-Trp6-LHRH, Triptorelin, Decapeptyl, Diphereline, Trelstar, Triptodur

10 amino acids, from first to lastQHWSYWLRPG

Evidence level: Large trials in people1,050 of 1,338 results come from studies in people, including randomized trials.

Results in people

1,050

78% of 1,338 results

Results in animals

256

19% of 1,338 results

Results in lab cells

2% of 1,338 results

From computer models

0% of 1,338 results

Overview

Triptorelin (Trelstar, Decapeptyl) at a glance

What it is	Synthetic analog, 10 amino acids
Approval	Approved in the US and EU (Trelstar)
In sport	Banned in sport (WADA S2.2.1)
Studies	345 studies with results. 270 of them gave triptorelin, with 1,338 results. 1,050 in people256 in animals32 in lab cells
Best study in people	Randomized controlled trial with 868 people (2019)
Clinical trials	207 registered: 44 active or planned, 40 with posted results
Community use	Trelstar is indicated for the treatment of advanced prostate cancer.

The science

What is triptorelin?

A GnRH agonist used in approved medicines for hormone suppression, with indications that depend on product and country.

Amino acids in one chain

The history of triptorelin

1979
The oldest paper on triptorelin in PepBank is from 1979.
2003November
A registered trial of triptorelin started (NCT00066703).

Triptorelin (Trelstar, Decapeptyl) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 10 amino acidsFrom the first amino acid to the last

Q1HWSY5WL+RPG10

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Triptorelin (Trelstar, Decapeptyl) is a synthetic analog of 10 amino acids, with no ring, 3 changed amino acids.

Formula

C₆₄H₈₂N₁₈O₁₃

Molecular weight

1,311.4 g/mol

CAS number

57773-63-4

Target

Gonadotropin-releasing hormone receptor (gene GNRHR): agonistEvidence: official prescribing information

Development

Multiple developers and marketing holders. Highest phase: past the trial stage (see status).

Identifiers

PubChem 25074470, UNII 9081Y98W2V, DrugBank DB06825, UniProt P01148

Full sequence, SMILES and InChIKey

InChIKey
VXKHXGOKWPXYNA-PGBVPBMZSA-N

SMILES
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8

See charge, composition and 3D structure on the Scientific page

The evidence

What triptorelin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people1,050 of 1,338 results come from studies in people, including randomized trials.

Sex hormones and fertility

782 results · 599 in people · 171 animal · 12 lab

Triptorelin did not significantly change implantation rates compared with no supplementation in frozen embryo transfer. Gynecological endocrinology, 2019

Top results

Triptorelin did not significantly change implantation rates compared with no supplementation in frozen embryo transfer. (Gynecological endocrinology, 2019)
In men with advanced prostate cancer, triptorelin produced a lower early castration rate than leuprolide. (BJU international, 2003)
In women undergoing ICSI, luteal-phase triptorelin increased implantation rates compared with placebo. (Human reproduction, 2006)

Growth hormone and growth

79 results · 77 in people · 1 animal · 1 lab

In girls with precocious puberty, triptorelin increased predicted adult height compared with before treatment. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006

Top results

In girls with precocious puberty, triptorelin increased predicted adult height compared with before treatment. (Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006)
In breast cancer patients, IGF-I increased during triptorelin alone. (The Journal of steroid biochemistry and molecular biology, 2000)
In children with early puberty, growth slowed during triptorelin treatment. (The Journal of clinical endocrinology and metabolism, 1986)

Bones and joints

74 results · 71 in people · 3 animal

In girls with early puberty, skeletal maturation slowed significantly during triptorelin treatment. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2004

Top results

In girls with early puberty, skeletal maturation slowed significantly during triptorelin treatment. (Zhonghua er ke za zhi = Chinese journal of pediatrics, 2004)
In girls with precocious puberty, subcutaneous triptorelin reduced the bone maturation ratio from 1.2 to 0.7 compared with before treatment. (Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006)
In women with hirsutism, Decapeptyl alone increased a marker of bone turnover. (The Journal of clinical endocrinology and metabolism, 1994)

Cancer

58 results · 52 in people · 2 animal · 4 lab

In high-risk prostate cancer after surgery, relapse-free survival did not differ significantly between triptorelin and surveillance. Asia-Pacific journal of clinical oncology, 2024

Top results

In high-risk prostate cancer after surgery, relapse-free survival did not differ significantly between triptorelin and surveillance. (Asia-Pacific journal of clinical oncology, 2024)
In women with uterine myoma, Diphereline reduced individual tumor nodule volume by 21-97%. (Saudi medical journal, 2007)
In men with prostate cancer, PSA decreased similarly during triptorelin and leuprolide treatment. (European urology, 1997)

Weight and appetite

31 results · 28 in people · 3 animal

In men with advanced prostate cancer, weight increased less with triptorelin than with orchiectomy. BJU international, 2019

Top results

In men with advanced prostate cancer, weight increased less with triptorelin than with orchiectomy. (BJU international, 2019)
In men with advanced prostate cancer, total body fat increased less with triptorelin than with orchiectomy. (BJU international, 2019)
In healthy men, triptorelin raised leptin after five weeks. (European journal of endocrinology, 1999)

Surgery and procedures

20 results · 20 in people

In women undergoing myomectomy, bleeding was more severe with diphereline than vaginal danazol. European journal of obstetrics, gynecology, and reproductive biology, 2016

Top results

In women undergoing myomectomy, bleeding was more severe with diphereline than vaginal danazol. (European journal of obstetrics, gynecology, and reproductive biology, 2016)
Women had similar complications, postoperative pain and satisfaction with triptorelin, letrozole, ulipristal acetate or direct surgery. (European journal of obstetrics, gynecology, and reproductive biology, 2015)
In women with fibroids, vaginal surgery was suitable more often after triptorelin than with immediate surgery. (British journal of obstetrics and gynaecology, 1998)

All 345 triptorelin studies by area Open the Scientific page

Key triptorelin studies

Studies in people come first, then studies in animals and in the lab.

People
The addition of single dose GnRH agonist to luteal phase support in artificial cycle frozen embryo transfer: a randomized clinical trial
Ye et al. 2019 · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 868 people · cited by 14
5 results
People
Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles
Tesarik et al. 2006 · Human reproduction (Oxford, England) · 600 people · cited by 89
6 results
People
GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controlled trial
Bellver et al. 2010 · Fertility and sterility · 344 people · cited by 8
5 results
People
Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer
Heyns et al. 2003 · BJU international · 284 people · cited by 65
7 results
People
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial
Del et al. 2011 · JAMA · 281 people · cited by 255
1 result

All 345 Triptorelin (Trelstar, Decapeptyl) studies

Triptorelin clinical trials

ClinicalTrials.gov lists 207 trials of triptorelin. 44 are active or planned, and 40 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase 3completed3,066 people

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase 3completed2,672 people

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3status unknown1,792 planned

All 58 Triptorelin (Trelstar, Decapeptyl) trials

Status and safety

Is triptorelin approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.1.

Yes. Approved in the US and EU (Trelstar). The FDA label for Trelstar says: “Treatment of advanced prostate cancer” Banned in sport (WADA S2.2.1).

Laws and labels change, so check the regulator for the current status.

Triptorelin side effects and safety

PepBank has 164 safety results from studies of triptorelin. 160 of them come from studies in people.

Safety results from studies (164)

In oocyte donors, ovarian hyperstimulation syndrome was less frequent with triptorelin than recombinant HCG. (Reproductive biomedicine online, 2009)
In antagonist IVF cycles, luteal triptorelin did not increase ovarian hyperstimulation risk compared with progesterone alone. (Reproductive biology and endocrinology, 2019)
In women undergoing IUI, miscarriage rates were similar with triptorelin and placebo. (Fertility and sterility, 2010)
In patients undergoing IUI, miscarriages occurred in 2.4% with triptorelin and none without luteal support. (Gynecological endocrinology, 2022)
In healthy premenopausal women, triptorelin alone was well tolerated. (Breast cancer research and treatment, 2009)
Adding triptorelin did not significantly change pregnancy loss rates compared with luteal support alone during frozen-thawed embryo transfer. (The Journal of international medical research, 2021)
Triptorelin did not significantly change miscarriage rates compared with no supplementation in frozen embryo transfer. (Gynecological endocrinology, 2019)
In men with advanced prostate cancer, both triptorelin and leuprolide were well tolerated. (BJU international, 2003)
In patients with early breast cancer, triptorelin plus chemotherapy gave similar disease-free survival to chemotherapy alone. (Journal of the National Cancer Institute, 2022)
In women after endometrioma surgery, bone pain after 9 weeks did not differ between triptorelin and leuprorelin. (European journal of obstetrics, gynecology, and reproductive biology, 2014)
In Chinese women, cancellation for ovarian hyperstimulation risk occurred in 7.5% with triptorelin versus 1.8% with ganirelix (P = 0.06). (Gynecological endocrinology, 2012)
In oocyte donors, no mild OHSS occurred with triptorelin, versus nine cases with hCG. (Gynecological endocrinology, 2009)
In ovarian stimulation patients, abortion rates did not differ significantly between half-dose and full-dose triptorelin. (Human reproduction, 2004)
In oocyte donors receiving triptorelin, one patient developed early-onset severe ovarian hyperstimulation syndrome. (Fertility and sterility, 2016)
In endometriosis patients, half-dose triptorelin caused fewer menopause symptoms than the draw-back regimen. (Zhonghua yi xue za zhi, 2013)
In women undergoing hysteroscopy, neither the diphereline nor danazol group had intra-operative complications. (European journal of obstetrics, gynecology, and reproductive biology, 2016)
In frozen embryo transfer cycles, additional triptorelin did not significantly reduce miscarriage rates versus standard HRT. (Journal of gynecology obstetrics and human reproduction, 2018)
In IVF patients, abortion rates did not differ significantly between reduced-dose and depot triptorelin. (Human reproduction, 2001)
In women with uterine leiomyoma, 71% reported adverse events in both triptorelin and leuprorelin groups. (Zhonghua fu chan ke za zhi, 2005)
In women after endometriosis surgery, 85.1% reported adverse events with triptorelin, compared with 87.7% with dienogest. (Fertility and sterility, 2002)
In women with endometriosis and infertility, adverse reaction incidence was similar with triptorelin and gestrinone. (Pakistan journal of medical sciences, 2018)
In women undergoing fertility preservation, no ovarian hyperstimulation syndrome occurred with triptorelin alone. (Fertility and sterility, 2026)
In women with uterine myoma, fewer side effects were noted with cabergoline than with Diphereline. (Saudi medical journal, 2007)
In women with endometriosis, side effects, mainly hot flushes, occurred more often with triptorelin than placebo. (Fertility and sterility, 1998)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.1 mg single dose	Human	human	subcutaneous	day 3 after embryo transfer	Randomized trial in people · n = 868	Ye 2019
0.1 mg	Human	human	injection	Single injection on day 6 after ICSI	Randomized trial in people · n = 600	Tesarik 2006
0.1 mg	Human	human	subcutaneous	Single injection	Randomized trial in people · n = 344	Bellver 2010
3.75 mg	Human	human	intramuscular	9 months	Randomized trial in people · n = 284	Heyns 2003
3.75 mg every 4 weeks	Human	human	intramuscular	Duration of chemotherapy	Randomized trial in people · n = 281	Del 2011
11.25 mg at baseline and at 3 and 6 months	Human	human	Not reported	9 months	Randomized trial in people · n = 226	Matveev 2024
Two injections of 0.1mg	Human	human	injection	Not reported	Randomized trial in people · n = 220	Gogce 2015
Single 0.1 mg dose	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 200	Davar 2015
0.1 mg once on day 3 after embryo transfer	Human	human	Not reported	Not reported	Randomized trial in people · n = 180	Razieh 2009
0.2, 0.3 or 0.4 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 165	Vuong 2016
0.1 mg once	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 163	Leppänen 2022
0.2 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 160	Maged 2021
0.2 mg single bolus	Human	human	Not reported	Not reported	Randomized trial in people · n = 100	Melo 2009
3.75 mg monthly	Human	human	intramuscular	6 months	Randomized trial in people · n = 68	Abbou 1997
22.5 mg/24 week depot injections	Human	human	Not reported	48 weeks	Randomized trial in people · n = 58	Østergren 2019
3.75 mg on day 1 of every cycle	Human	human	intramuscular	six 28-day cycles	Randomized trial in people · n = 51	Dellapasqua 2019
120 μg/kg body weight	Human	human	Not reported	Not reported	Randomized trial in people	Brunner 2015
0.4 mg	Human	human	Not reported	Not reported	Randomized trial in people	Vuong 2016
3.75 mg on days 1 and 29	Human	human	Not reported	8 weeks	Randomized trial in people	Jannuzzo 2009
0.1 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 893	Wang 2021
Two boluses of 0.1 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 287	Alsbjerg 2022
15, 50 or 100 microg daily	Human	human	Not reported	Not reported	Randomized trial in people · n = 240	Janssens 2000
0.2 mg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 221	Schachter 2008
0.2 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 212	Galindo 2009
0.2 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 192	Eftekhar 2017
1.875 mg, 3.75 mg then 1.875 mg, or 3.75 mg every 28 days	Human	human	intramuscular	Not reported	Randomized trial in people · n = 186	Liu 2013
1.87 mg depot versus 3.75 mg depot	Human	human	Not reported	Not reported	Randomized trial in people · n = 180	Dal 2004
two doses, 8 weeks before starting the endometrial preparation	Human	human	Not reported	Not reported	Randomized trial in people · n = 178	Aghahoseini 2020
1.875 mg every 28 days for 6 injections	Human	human	intramuscular	Not reported	Randomized trial in people · n = 151	Liu 2013
0.1 mg, single dose	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 144	Seikkula 2018
3.75 mg monthly	Human	human	Not reported	Not reported	Randomized trial in people · n = 135	Emons 1996
100 microg daily reduced to 50 microg at FSH stimulation	Human	human	Not reported	Not reported	Randomized trial in people · n = 132	Dal 2001
1.87 mg	Human	human	Not reported	Single dose	Randomized trial in people · n = 126	Tehraninejad 2010
3.75 mg every 28 days	Human	human	intramuscular	3 months	Randomized trial in people · n = 125	Zhou 2005
3.75 mg every 4 weeks	Human	human	intramuscular	16 weeks	Randomized trial in people · n = 120	Cosson 2002
0.2 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 106	Kolibianakis 2005
3.75 mg, three injections 28 days apart	Human	human	intramuscular	Not reported	Randomized trial in people · n = 90	Maged 2018
3.75 mg (extended-interval regimen)	Human	human	intramuscular (extended-interval regimen)	4 doses every 6 weeks (extended); 6 doses every 4 weeks (conventional)	Randomized trial in people · n = 70	Kang 2010
3.75 mg at 4-week intervals	Human	human	intramuscular	3 months	Randomized trial in people · n = 67	Kuhn 1997
11.25 mg once	Human	human	Not reported	3 months	Randomized trial in people · n = 65	Li 2008

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label describes prescription use. These regimens are label information and are not community practice.

Reported routines and cautions

What people use it for

Trelstar is indicated for the treatment of advanced prostate cancer.S1

Reported regimens

Regimens that community sources report for Triptorelin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Trelstar advanced prostate cancer, 3.75 mg depotOfficial label dosing of an approved product	intramuscular injection	3.75 mg per dose	every 4 weeks	Not stated	Official US prescribing information.	S1
Trelstar advanced prostate cancer, 11.25 mg depotOfficial label dosing of an approved product	intramuscular injection	11.25 mg per dose	every 12 weeks	Not stated	Official US prescribing information.	S1
Trelstar advanced prostate cancer, 22.5 mg depotOfficial label dosing of an approved product	intramuscular injection	22.5 mg per dose	every 24 weeks	Not stated	Official US prescribing information.	S1

Cautions

The label warns about an initial testosterone rise, hyperglycemia, and cardiovascular risk.S1

Community sources

S1US Triptorelin prescribing information (opens in a new tab)dailymed.nlm.nih.gov

Gaps

This review uses the supplied official label. It does not assess other community practices. The record does not reproduce every administration instruction.

Questions and more

Ask a question about triptorelin

The answer links to every study it uses.

What does the evidence say about triptorelin?Is triptorelin tested in people?Compare with Oxytocin Compare with Kisspeptin-10

Sources

Database: PepBank data for triptorelin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about triptorelin

Triptorelin (Trelstar, Decapeptyl)

ApprovedBanned in sport

Also known as D-Trp6-LHRH, Triptorelin, Decapeptyl, Diphereline, Trelstar, Triptodur

What it is

Synthetic analog, 10 amino acids

Approval

Approved in the US and EU (Trelstar)

In sport

Banned in sport (WADA S2.2.1)

Studies

345 studies with results. 270 of them gave triptorelin, with 1,338 results.
1,050 in people256 in animals32 in lab cells

Best study in people

Randomized controlled trial with 868 people (2019)

Clinical trials

207 registered: 44 active or planned, 40 with posted results

Community use

Trelstar is indicated for the treatment of advanced prostate cancer.

Dose as reported

Class

Species

Route

Duration

Design

Source

0.1 mg single dose

Human

human

subcutaneous

day 3 after embryo transfer

Randomized trial in people · n = 868

Ye 2019

0.1 mg

Human

human

injection

Single injection on day 6 after ICSI

Randomized trial in people · n = 600

Tesarik 2006

0.1 mg

Human

human

subcutaneous

Single injection

Randomized trial in people · n = 344

Bellver 2010

3.75 mg

Human

human

intramuscular

9 months

Randomized trial in people · n = 284

Heyns 2003

3.75 mg every 4 weeks

Human

human

intramuscular

Duration of chemotherapy

Randomized trial in people · n = 281

Del 2011

11.25 mg at baseline and at 3 and 6 months

Human

human

Not reported

9 months

Randomized trial in people · n = 226

Matveev 2024

Two injections of 0.1mg

Human

human

injection

Not reported

Randomized trial in people · n = 220

Gogce 2015

Single 0.1 mg dose

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 200

Davar 2015

0.1 mg once on day 3 after embryo transfer

Human

human

Not reported

Randomized trial in people · n = 180

Razieh 2009

0.2, 0.3 or 0.4 mg

Human

human

Not reported

Randomized trial in people · n = 165

Vuong 2016

0.1 mg once

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 163

Leppänen 2022

0.2 mg

Human

human

Not reported

Randomized trial in people · n = 160

Maged 2021

0.2 mg single bolus

Human

human

Not reported

Randomized trial in people · n = 100

Melo 2009

3.75 mg monthly

Human

human

intramuscular

6 months

Randomized trial in people · n = 68

Abbou 1997

22.5 mg/24 week depot injections

Human

human

Not reported

48 weeks

Randomized trial in people · n = 58

Østergren 2019

3.75 mg on day 1 of every cycle

Human

human

intramuscular

six 28-day cycles

Randomized trial in people · n = 51

Dellapasqua 2019

120 μg/kg body weight

Human

human

Not reported

Randomized trial in people

Brunner 2015

0.4 mg

Human

human

Not reported

Randomized trial in people

Vuong 2016

3.75 mg on days 1 and 29

Human

human

Not reported

8 weeks

Randomized trial in people

Jannuzzo 2009

0.1 mg

Human

human

Not reported

Randomized trial in people · n = 893

Wang 2021

Two boluses of 0.1 mg

Human

human

Not reported

Randomized trial in people · n = 287

Alsbjerg 2022

15, 50 or 100 microg daily

Human

human

Not reported

Randomized trial in people · n = 240

Janssens 2000

0.2 mg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 221

Schachter 2008

0.2 mg

Human

human

Not reported

Randomized trial in people · n = 212

Galindo 2009

0.2 mg

Human

human

Not reported

Randomized trial in people · n = 192

Eftekhar 2017

1.875 mg, 3.75 mg then 1.875 mg, or 3.75 mg every 28 days

Human

human

intramuscular

Not reported

Randomized trial in people · n = 186

Liu 2013

1.87 mg depot versus 3.75 mg depot

Human

human

Not reported

Randomized trial in people · n = 180

Dal 2004

two doses, 8 weeks before starting the endometrial preparation

Human

human

Not reported

Randomized trial in people · n = 178

Aghahoseini 2020

1.875 mg every 28 days for 6 injections

Human

human

intramuscular

Not reported

Randomized trial in people · n = 151

Liu 2013

0.1 mg, single dose

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 144

Seikkula 2018

3.75 mg monthly

Human

human

Not reported

Randomized trial in people · n = 135

Emons 1996

100 microg daily reduced to 50 microg at FSH stimulation

Human

human

Not reported

Randomized trial in people · n = 132

Dal 2001

1.87 mg

Human

human

Not reported

Single dose

Randomized trial in people · n = 126

Tehraninejad 2010

3.75 mg every 28 days

Human

human

intramuscular

3 months

Randomized trial in people · n = 125

Zhou 2005

3.75 mg every 4 weeks

Human

human

intramuscular

16 weeks

Randomized trial in people · n = 120

Cosson 2002

0.2 mg

Human

human

Not reported

Randomized trial in people · n = 106

Kolibianakis 2005

3.75 mg, three injections 28 days apart

Human

human

intramuscular

Not reported

Randomized trial in people · n = 90

Maged 2018

3.75 mg (extended-interval regimen)

Human

human

intramuscular (extended-interval regimen)

4 doses every 6 weeks (extended); 6 doses every 4 weeks (conventional)

Randomized trial in people · n = 70

Kang 2010

3.75 mg at 4-week intervals

Human

human

intramuscular

3 months

Randomized trial in people · n = 67

Kuhn 1997

11.25 mg once

Human

human

Not reported

3 months

Randomized trial in people · n = 65

Li 2008

Context

Route

Amount

How often

How long

Agreement

Sources

Trelstar advanced prostate cancer, 3.75 mg depotOfficial label dosing of an approved product

intramuscular injection

3.75 mg per dose

every 4 weeks

Not stated

Official US prescribing information.

Trelstar advanced prostate cancer, 11.25 mg depotOfficial label dosing of an approved product

intramuscular injection

11.25 mg per dose

every 12 weeks

Not stated

Official US prescribing information.

Trelstar advanced prostate cancer, 22.5 mg depotOfficial label dosing of an approved product

intramuscular injection

22.5 mg per dose

every 24 weeks

Not stated

Official US prescribing information.

Triptorelin (Trelstar, Decapeptyl)

Triptorelin (Trelstar, Decapeptyl) at a glance

What is triptorelin?

The history of triptorelin

Triptorelin (Trelstar, Decapeptyl) structure and chemistry

What triptorelin studies show

Sex hormones and fertility

Growth hormone and growth

Bones and joints

Cancer

Weight and appetite

Surgery and procedures

Key triptorelin studies

Triptorelin clinical trials

Is triptorelin approved?

Triptorelin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about triptorelin

Related peptides

Sources

Triptorelin (Trelstar, Decapeptyl)

Triptorelin (Trelstar, Decapeptyl) at a glance

What is triptorelin?

The history of triptorelin

Triptorelin (Trelstar, Decapeptyl) structure and chemistry

What triptorelin studies show

Sex hormones and fertility

Growth hormone and growth

Bones and joints

Cancer

Weight and appetite

Surgery and procedures

Key triptorelin studies

Triptorelin clinical trials

Is triptorelin approved?

Triptorelin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about triptorelin

Related peptides

Sources